Capital funding was the preserve of central government, which considered that so far as the laboratory at BPL was concerned "expenditure on up-grading should be reviewed and minimised pending a decision on the laboratory's future."
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Viral Inactivation